Pacritinib versus best available therapy for the treatment of myelofibrosis irrespective of baseline cytopenias (PERSIST-1): an international, randomised, phase 3 trial

RA Mesa; AM Vannucchi; A Mead; M Egyed; A Szoke; A Suvorov; J Jakucs; A Perkins; R Prasad; J Mayer; J Demeter; P Ganly; JW Singer; HF Zhou; JP Dean; Peter te Boekhorst; J Nangalia; JJ Kiladjian; CN Harrison

doi:10.1016/s2352-3026(17)30027-3

Pacritinib versus best available therapy for the treatment of myelofibrosis irrespective of baseline cytopenias (PERSIST-1): an international, randomised, phase 3 trial

RA Mesa, AM Vannucchi, A Mead, M Egyed, A Szoke, A Suvorov, J Jakucs, A Perkins, R Prasad, J Mayer, J Demeter, P Ganly, JW Singer, HF Zhou, JP Dean, Peter te Boekhorst, J Nangalia, JJ Kiladjian, CN Harrison

Hematology

Research output: Contribution to journal › Article › Academic › peer-review

248 Citations (Scopus)

Original language	Undefined/Unknown
Pages (from-to)	E225-E236
Journal	Lancet Haematology
Volume	4
Issue number	5
DOIs	https://doi.org/10.1016/s2352-3026(17)30027-3
Publication status	Published - 2017

Research programs

EMC OR-01

Access to Document

10.1016/s2352-3026(17)30027-3

http://hdl.handle.net/1765/98799

Cite this

Mesa, RA., Vannucchi, AM., Mead, A., Egyed, M., Szoke, A., Suvorov, A., Jakucs, J., Perkins, A., Prasad, R., Mayer, J., Demeter, J., Ganly, P., Singer, JW., Zhou, HF., Dean, JP., te Boekhorst, P., Nangalia, J., Kiladjian, JJ., & Harrison, CN. (2017). Pacritinib versus best available therapy for the treatment of myelofibrosis irrespective of baseline cytopenias (PERSIST-1): an international, randomised, phase 3 trial. Lancet Haematology, 4(5), E225-E236. https://doi.org/10.1016/s2352-3026(17)30027-3

@article{44cf67aaf5d24c8dbcf61b6c55883a6a,

title = "Pacritinib versus best available therapy for the treatment of myelofibrosis irrespective of baseline cytopenias (PERSIST-1): an international, randomised, phase 3 trial",

author = "RA Mesa and AM Vannucchi and A Mead and M Egyed and A Szoke and A Suvorov and J Jakucs and A Perkins and R Prasad and J Mayer and J Demeter and P Ganly and JW Singer and HF Zhou and JP Dean and {te Boekhorst}, Peter and J Nangalia and JJ Kiladjian and CN Harrison",

year = "2017",

doi = "10.1016/s2352-3026(17)30027-3",

language = "Undefined/Unknown",

volume = "4",

pages = "E225--E236",

journal = "Lancet Haematology",

issn = "2352-3026",

publisher = "Lancet Publishing Group",

number = "5",

}

Mesa, RA, Vannucchi, AM, Mead, A, Egyed, M, Szoke, A, Suvorov, A, Jakucs, J, Perkins, A, Prasad, R, Mayer, J, Demeter, J, Ganly, P, Singer, JW, Zhou, HF, Dean, JP, te Boekhorst, P, Nangalia, J, Kiladjian, JJ & Harrison, CN 2017, 'Pacritinib versus best available therapy for the treatment of myelofibrosis irrespective of baseline cytopenias (PERSIST-1): an international, randomised, phase 3 trial', Lancet Haematology, vol. 4, no. 5, pp. E225-E236. https://doi.org/10.1016/s2352-3026(17)30027-3

TY - JOUR

T1 - Pacritinib versus best available therapy for the treatment of myelofibrosis irrespective of baseline cytopenias (PERSIST-1): an international, randomised, phase 3 trial

AU - Mesa, RA

AU - Vannucchi, AM

AU - Mead, A

AU - Egyed, M

AU - Szoke, A

AU - Suvorov, A

AU - Jakucs, J

AU - Perkins, A

AU - Prasad, R

AU - Mayer, J

AU - Demeter, J

AU - Ganly, P

AU - Singer, JW

AU - Zhou, HF

AU - Dean, JP

AU - te Boekhorst, Peter

AU - Nangalia, J

AU - Kiladjian, JJ

AU - Harrison, CN

PY - 2017

Y1 - 2017

U2 - 10.1016/s2352-3026(17)30027-3

DO - 10.1016/s2352-3026(17)30027-3

M3 - Article

SN - 2352-3026

VL - 4

SP - E225-E236

JO - Lancet Haematology

JF - Lancet Haematology

IS - 5

ER -